KnowTheStock
Log inCreate free account

Aclaris Therapeutics Inc

ACRS
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) · NASDAQ
$5.02last close · market cap 716.54 Million
Compare with…
22.1SCORE / 100
Our verdictSELLWeak Growth, Earnings/Profit is NegativeQtr Ending 2026-06-30 · trend negative

Why Sell

Balance sheet is strong; income statement is weak.

Next earnings: 2026-11-05, EPS Forecast: ($0.16)

What is strong
  • Current Asset to Current Liability Ratio is 3.46
  • Debt Ratio is 0.31
  • Total Debt to Total Assets Ratio is 0.0
What to watch
  • Revenue Growth is -51.05%
  • Operating Income is Negative but improving
  • Net Income is Negative but improving
  • Earnings Per Share (EPS) is Negative but improving
  • Net Margin is -921.5%
  • Current Debt to Net Income Ratio not available
  • Cash from Operations is Negative
  • Capital Expenditure not available
  • Net Increase in Cash is Negative
  • Investment Risk is High

What changed

Score by quarter

Rated Sell for the last 12 quarters. This quarter: +0.0.

203040Sep 2022Jun 2026

What the score is made of

Income statement0.0 +0.0
Balance sheet75.4 +0.0
Cash flow0.0 +0.0

Change vs previous quarter.

Key numbers · latest quarter

Revenue (TTM)8.22 Million-51.05 % growth
EPS-0.58
Profit margin-921.50 %Profit per $1 of sales
P-E ratio—Not available
Market cap716.54 MillionShares × price
Debt-equity ratio—Not available
Dividend0.00Per share, annual
Next earnings2026-11-05EPS forecast ($0.16)
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.

About Aclaris Therapeutics Inc

aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.

CEO
Neal Walker
Employees
62
Sector
Professional, Scientific, and Technical Services
Exchange
NASDAQ
aclaristx.com

Similar stocks

Loading…